|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ozols RF: Treatment goals in ovarian
cancer. Int J Gynecol Cancer 1 (15 Suppl). S3–S11. 2005. View Article : Google Scholar
|
|
3
|
Kleppe M, Amkreutz LC, Van Gorp T, Slangen
BF, Kruse AJ and Kruitwagen RF: Lymph-node metastasis in stage I
and II sex cord stromal and malignant germ cell tumours of the
ovary: A systematic review. Gynecol Oncol. 133:124–127. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Calin GA, Sevignani C, Dumitru CD, Hysolp
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayes J, Peruzzi PP and Lawler SE:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duan F, Liu W, Fu X, Feng Y, Dai L, Cui S
and Yang Z: Evaluating the prognostic value of miR-148/152 family
in cancers: Based on a systemic review of observational studies.
Oncotarget. 8:77999–78010. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou X, Zhao F, Wang ZN, Song YX, Chang H,
Chiang Y and Xu HM: Altered expression of miR-152 and miR-148a in
ovarian cancer is related to cell proliferation. Oncol Rep.
27:447–454. 2012.PubMed/NCBI
|
|
8
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma F, Feng Y, Li W, Li Z, Liu T and Li L:
miR-148a suppresses estrogen-induced viability and migration of
breast cancer cells via inhibition of estrogen receptor α
expression. Exp Ther Med. 13:2515–2522. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng
H and Lai M: MiR-148a promotes apoptosis by targeting Bcl-2 in
colorectal cancer. Cell Death Differ. 18:1702–1710. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing
C and Liu Z: Altered expression of miR-148a and miR-152 in
gastrointestinal cancers and its clinical significance. J
Gastrointest Surg. 14:1170–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murata T, Takayama K, Katayama S, Urano T,
Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y,
et al: miR-148a is an androgen-responsive microRNA that promotes
LNCaP prostate cell growth by repressing its target CAND1
expression. Prostate Cancer Prostatic Dis. 13:356–361. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li L, Liu Y, Guo Y, Liu B, Zhao Y, Li P,
Song F, Zheng H, Yu J, Song T, et al: Regulatory miR-148a-ACVR1/BMP
circuit defines a cancer stem cell-like aggressive subtype of
hepatocellular carcinoma. Hepatology. 61:574–584. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han C, Zheng W, Ge M, Wang K, Xiang Y and
Huang P: Downregulation of cyclin-dependent kinase 8 by
microRNA-148a suppresses proliferation and invasiveness of
papillary thyroid carcinomas. Am J Cancer Res. 7:2081–2090.
2017.PubMed/NCBI
|
|
15
|
Kim EA, Kim TG, Sung EG, Song IH, Kim JY,
Doh KO and Lee TJ: miR-148a increases the sensitivity to cisplatin
by targeting Rab14 in renal cancer cells. Int J Oncol. 50:984–992.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gong L, Wang C, Gao Y and Wang J:
Decreased expression of microRNA-148a predicts poor prognosis in
ovarian cancer and associates with tumor growth and metastasis.
Biomed Pharmacother. 83:58–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wen Z, Zhao S, Liu S, Liu Y, Li X and Li
S: MicroRNA-148a inhibits migration and invasion of ovarian cancer
cells via targeting sphingosine-1-phosphate receptor 1. Mol Med
Rep. 12:3775–3780. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaestner KH, Knochel W and Martinez DE:
Unified nomenclature for the winged helix/forkhead transcription
factors. Genes Dev. 14:142–146. 2000.PubMed/NCBI
|
|
19
|
Fu Z and Tindall DJ: FOXOs, cancer and
regulation of apoptosis. Oncogene. 27:2312–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kurman RJ, Carcangiu ML, Herrington CS and
Young RHE: WHO Classification of Tumours of Female Reproductive
Organs. (4th). IARC. (Lyon). 2014.
|
|
21
|
Paik ES, Lee YY, Lee EJ, Choi CH, Kim TJ,
Lee JW, Bae DS and Kim BG: Survival analysis of revised 2013 FIGO
staging classification of epithelial ovarian cancer and comparison
with previous FIGO staging classification. Obstet Gynecol Sci.
58:124–134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao S, Wen Z, Liu S, Liu Y, Li X, Ge Y
and Li S: MicroRNA-148a inhibits the proliferation and promotes the
paclitaxel-induced apoptosis of ovarian cancer cells by targeting
PDIA3. Mol Med Rep. 12:3923–3929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou M, Su Z, Zhang S, Zhuang L, Xie Y and
Li X: Suppressive role of microRNA-148a in cell proliferation and
invasion in ovarian cancer through targeting transforming growth
factor-β-induced 2. Oncol Res. 24:353–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang W, Dong J, Wang M, Yao S, Tian X, Cui
X, Fu S and Zhang S: miR-148a-3p suppresses epithelial ovarian
cancer progression primarily by targeting c-Met. Oncol Lett.
15:6131–6136. 2018.PubMed/NCBI
|
|
26
|
Ghoshchoudhury T, Xiao W, Gunaratne PH and
Anderson ML: Loss of miR-148a/b expression promotes ovarian cancer
by targeting Erbb3 and MYB. Gynecol Oncol. 125 (Suppl 1):S982012.
View Article : Google Scholar
|
|
27
|
Carbajo-Pescador S, Mauriz JL,
García-Palomo A and González-Gallego J: FoxO proteins: Regulation
and molecular targets in liver cancer. Curr Med Chem. 21:1231–1246.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang
F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al: IkappaB kinase
promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell.
117:225–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dobbin ZC and Landen CN: The importance of
the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int
J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ataiekachoie P, Badar S, Morris DL and
Pourgholami MH: Minocycline targets the NF-κB nexus through
suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer. Mol
Cancer Res. 11:1279–1291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu R, Liu F, Li L, Sun M and Chen K:
MiR-498 regulated FOXO3 expression and inhibited the proliferation
of human ovarian cancer cells. Biomed Pharmacother. 72:52–57. 2015.
View Article : Google Scholar : PubMed/NCBI
|
